{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:53:11Z","timestamp":1779292391635,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T00:00:00Z","timestamp":1370908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s10067-013-2293-4","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T06:29:30Z","timestamp":1370845770000},"page":"1677-1681","source":"Crossref","is-referenced-by-count":28,"title":["Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?"],"prefix":"10.1007","volume":"32","author":[{"given":"Emilio","family":"Besada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes C.","family":"Nossent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,11]]},"reference":[{"key":"2293_CR1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","volume":"42","author":"M Ward","year":"1999","unstructured":"Ward M, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue diseases. The role of the experience in diagnosis and mortality. Arthritis Rheum 42:780\u20139","journal-title":"Arthritis Rheum"},{"key":"2293_CR2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","volume":"34","author":"KA Sepkowitz","year":"2002","unstructured":"Sepkowitz KA (2002) Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 34:1098\u2013107","journal-title":"Clin Infect Dis"},{"key":"2293_CR3","author":"I Martin-Garrido","year":"2012","unstructured":"Martin-Garrido I, Carmona EM, Specks U et al (2012) Pneumocystis pneumonia in patients treated with rituximab. Chest. doi: 10.1378\/chest.12-0477","journal-title":"Chest"},{"key":"2293_CR4","first-page":"795","volume":"151","author":"FP Ognibene","year":"1995","unstructured":"Ognibene FP, Shelhammer JH, Hoffman GS et al (1995) Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis. Am J Respir Crit Care Med 151:795\u20139","journal-title":"Am J Respir Crit Care Med"},{"key":"2293_CR5","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","volume":"40","author":"L Guillevin","year":"1997","unstructured":"Guillevin L, Cordier JF, Lhote F et al (1997) A prospective multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener\u2019s granulomatosis. Arthritis Rheum 40:2187\u201398","journal-title":"Arthritis Rheum"},{"key":"2293_CR6","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","volume":"82","author":"H Green","year":"2007","unstructured":"Green H, Paul M, Vidal L et al (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomised controlled trials. Mayo Clin Proc 82:1052\u20139","journal-title":"Mayo Clin Proc"},{"key":"2293_CR7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.23822","volume":"59","author":"A Suryaprasad","year":"2008","unstructured":"Suryaprasad A, Stone JH (2008) When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum 59:1034\u20139","journal-title":"Arthritis Rheum"},{"key":"2293_CR8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessels vasculitis. Ann Rheum Dis 68:310\u20137","journal-title":"Ann Rheum Dis"},{"key":"2293_CR9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Cohen Tevaert JW, Hauser T et al (2010) Randomized trial of rituximab versus cyclophosphamide in ANCA-associated renal vasculitis \u2018RITUXVAS\u2019. N Engl J Med 363:211\u201320","journal-title":"N Engl J Med"},{"key":"2293_CR10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Seo P et al (2010) Rituximab versus cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE). N Engl J Med 363:221\u201332","journal-title":"N Engl J Med"},{"key":"2293_CR11","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.08821209","volume":"5","author":"EP Rhee","year":"2010","unstructured":"Rhee EP, Laliberte KA, Niles JL (2010) Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 5:1394\u20131400","journal-title":"Clin J Am Soc Nephrol"},{"key":"2293_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3899\/jrheum.110143","volume":"39","author":"C Roubaud-Baudron","year":"2012","unstructured":"Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N et al (2012) Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 39:125\u201330","journal-title":"J Rheumatol"},{"key":"2293_CR13","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"RM Smith","year":"2012","unstructured":"Smith RM, Jones RB, Guerry MJ et al (2012) Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 64:3760\u201369","journal-title":"Arthritis Rheum"},{"key":"2293_CR14","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","volume":"64","author":"R Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba R, Golbin JM, Keogh KA et al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): ten-year experience at a single center. Arthritis Rheum 64:3770\u20138","journal-title":"Arthritis Rheum"},{"key":"2293_CR15","author":"S Mori","year":"2012","unstructured":"Mori S, Sugimoto M (2012) Pneumocystis jiroveci infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology. doi: 10.1093\/rheumatology\/kes244","journal-title":"Rheumatology"},{"key":"2293_CR16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/rheumatology\/keq314","volume":"50","author":"A Mekinian","year":"2011","unstructured":"Mekinian A, Durand-Joly I, Hatron PY et al (2011) Pneumocystis jiroveci colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology 50:569\u201377","journal-title":"Rheumatology"},{"key":"2293_CR17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/03009742.2011.630328","volume":"41","author":"C Fritzsche","year":"2012","unstructured":"Fritzsche C, Riebold D, Munk-Hartig AK et al (2012) High prevalence of Pneumocystis jiroveci colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy. Scand J Rheumatol 41:208\u201313","journal-title":"Scand J Rheumatol"},{"key":"2293_CR18","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3899\/jrheum.091294","volume":"37","author":"S Mori","year":"2010","unstructured":"Mori S, Cho I, Sugimoto M (2010) A cluster of Pneumocystis jiroveci infection among outpatients with rheumatoid arthritis. J Rheumatol 37:1547\u20138","journal-title":"J Rheumatol"},{"key":"2293_CR19","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3899\/jrheum.081270","volume":"36","author":"S Mori","year":"2009","unstructured":"Mori S, Cho I, Sugimoto M (2009) Follow-up study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol 36:1600\u20135","journal-title":"J Rheumatol"},{"key":"2293_CR20","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.4049\/jimmunol.176.10.6147","volume":"176","author":"FE Lund","year":"2006","unstructured":"Lund FE, Hollifield M, Schuer K et al (2006) B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 176:6147\u201354","journal-title":"J Immunol"},{"key":"2293_CR21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/10428191003699860","volume":"51","author":"S Kamel","year":"2010","unstructured":"Kamel S, O\u2019Connor S, Lee N et al (2010) High incidence of Pneumocystis jiroveci pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine and prednisolone. Leuk Lymphoma 51:797\u2013801","journal-title":"Leuk Lymphoma"},{"key":"2293_CR22","author":"T Kim","year":"2012","unstructured":"Kim T, Choi SH, Kim SH et al (2012) Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy. Ann Hematol. doi: 10.1007\/s00277-012-1592-1","journal-title":"Ann Hematol"},{"key":"2293_CR23","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3109\/10428194.2010.506569","volume":"51","author":"K Hashimoto","year":"2010","unstructured":"Hashimoto K, Kobayashi Y, Asakura Y et al (2010) Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count with B cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma 51:1816\u201321","journal-title":"Leuk Lymphoma"},{"key":"2293_CR24","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3109\/10428190903258780","volume":"50","author":"H Katsuya","year":"2009","unstructured":"Katsuya H, Suzumiya J, Sasaki H et al (2009) Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 50:1818\u201323","journal-title":"Leuk Lymphoma"},{"key":"2293_CR25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.10564","volume":"92","author":"A Kolstad","year":"2007","unstructured":"Kolstad A, Holte H, Foss\u00e5 A et al (2007) Pneumocystis jiroveci pneumonia in B cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 92:139\u201340","journal-title":"Haematologica"},{"key":"2293_CR26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0609.2007.00994.x","volume":"80","author":"AC Venhuizen","year":"2007","unstructured":"Venhuizen AC, Hustinx WN, van Houte AJ et al (2007) Three cases of Pneumocystis jiroveci pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B cell non-Hodgkin\u2019s lymphoma. Eur J Haematol 80:275\u20136","journal-title":"Eur J Haematol"},{"key":"2293_CR27","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJM199806113382407","volume":"338","author":"JA Fishman","year":"1998","unstructured":"Fishman JA, Rubin RH (1998) Infection in organ-transplant recipient. N Engl J Med 338:1741\u201351","journal-title":"N Engl J Med"},{"key":"2293_CR28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1440-1797.2009.01168.x","volume":"14","author":"E Shelton","year":"2009","unstructured":"Shelton E, Yong M, Cohney S (2009) Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 14:696\u20139","journal-title":"Nephrology"},{"key":"2293_CR29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","volume":"71","author":"JU Holle","year":"2012","unstructured":"Holle JU, Dubrau C, Herlyn K et al (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 71:327\u201333","journal-title":"Ann Rheum Dis"},{"key":"2293_CR30","author":"P Roll","year":"2012","unstructured":"Roll P, Ostermeier E, Haubitz M et al (2012) Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German Registry (GRAID). J Rheumatol. doi: 10.3899\/jrheum.120482","journal-title":"J Rheumatol"},{"key":"2293_CR31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-3083.2012.02747.x","volume":"76","author":"R Pullerits","year":"2012","unstructured":"Pullerits R, Ljevakt M, Vikgren J et al (2012) Off-trial evaluation of the B cell targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Scand J Immunol 76:411\u201320","journal-title":"Scand J Immunol"},{"key":"2293_CR32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/03009742.2011.620573","volume":"41","author":"M Wendt","year":"2012","unstructured":"Wendt M, Gunnarson I, Bratt J et al (2012) Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol 41:116\u20139","journal-title":"Scand J Rheumatol"},{"issue":"supplement 3","key":"2293_CR33","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.3949\/ccjm.79.s3.11","volume":"79","author":"U Specks","year":"2012","unstructured":"Specks U (2012) Biologic agents in the treatment of granulomatosis with polyangiitis. Cleve Clin J Med 79(supplement 3):S50\u201353","journal-title":"Cleve Clin J Med"},{"key":"2293_CR34","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3899\/jrheum.091426","volume":"37","author":"LK Stamp","year":"2010","unstructured":"Stamp LK, Hurst M (2010) Is there a role for consensus guidelines for P. jiroveci prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol 37:686\u20138","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2293-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-013-2293-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2293-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:57:26Z","timestamp":1559120246000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-013-2293-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["2293"],"URL":"https:\/\/doi.org\/10.1007\/s10067-013-2293-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,11]]}}}